AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

1(Currently Amended). A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
wherein,

M, M1, and M2, independently are CH ~~or N~~;

W represents  or $(CH_2)_nR_9$;

R represents hydrogen, or C_{1-6} alkyl;

X represents $-(CHR_7)_p-$, ~~or a bond~~;

Y represents $-(CH_2)_r-$, $-CO(CH_2)_n-$, $-SO_2-$, -O-, -S-, -CH(OR')-, or CONR';

R' represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

or, R' and R_6 taken together with the intervening N atom of CONR' of Y to form a 4-10 membered carbocyclic or heterocyclic ring ~~optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and~~ optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

Q represents N, CR^y, or O, wherein R_2 is absent when Q is O;

R^y represents H, C_{1-10} alkyl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{5-10}$ heteroaryl, $-N(R)_2$, -COOR, or $-(CH_2)_nC_{6-10}$ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-5 groups selected from R^a;

or, R_2-Q-R_3 form a 3-15 membered carbocyclic or heterocyclic ring or fused ring, optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-5 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R_w represents H, C_{1-6} alkyl, $-C(O)C_{1-6}$ alkyl, $-C(O)OC_{1-6}$ alkyl, $-SO_2N(R)_2$, $-SO_2C_{1-6}$ alkyl, $-SO_2C_{6-10}$ aryl, NO_2, CN or $-C(O)N(R)_2$;

R_2 represents hydrogen, C_{1-10} alkyl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{5-10}$ heteroaryl, $-N(R)_2$, -COOR, or $-(CH_2)_nC_{6-10}$ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R_3 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{5-10}$ heteroaryl, $-(CH_2)_nCOOR$, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nNHR_8$, $-(CH_2)_nN(R)_2$, $-(CH_2)_nNHCOOR$, $-(CH_2)_nN(R_8)CO_2R$, $-(CH_2)_nN(R_8)COR$, $-(CH_2)_nNHCOR$, $-(CH_2)_nCONH(R_8)$, aryl, $-(CH_2)_nC_{1-6}$ alkoxy, CF_3, $-(CH_2)_nSO_2R$, $-(CH_2)_nSO_2N(R)_2$, $-(CH_2)_nCON(R)_2$, $-(CH_2)_nCONHC(R)_3$, $-(CH_2)_nCOR_8$, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of R^a;

R_4 and R_5 independently represent hydrogen, C_{1-6} alkoxy, OH, ~~$OCOR_3$~~, C_{1-6} alkyl, ~~COOR~~, SO_3H, ~~$O(CH_2)_nN(R)_2$~~, ~~$O(CH_2)_nCO_2R$~~, C_{1-6} alkylcarbonyl, S(O)qR^y, $(CH_2)_nOPO(OH)_2$, $O(CH_2)_nOPO(OH)_2$, ~~$N(R)_2$~~, CF_3, nitro, cyano or halogen where said alkyl, and alkoxy, are optionally substituted with 1-7 groups of R^a;

R_6 represents hydrogen, C_{1-10} alkyl, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nC_{5-10}$ heteroaryl, (C_{6-10} aryl)O-, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, -COOR, $-C(O)CO_2R$, said

aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a;

R_7 represents hydrogen, C_{1-6} alkyl, $-(CH_2)_nCOOR$ or $-(CH_2)_nN(R)_2$,

R_8 represents $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_n$ 3-10 heterocyclyl, C_{1-6} alkoxy or $-(CH_2)_nC_{5-10}$ heteroaryl, said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R_9 represents C_{1-10} alkyl, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nC_{5-10}$ heteroaryl, or $-N(R)_2$ wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with 1-3 groups selected from R^a;

R^a represents F, Cl, Br, I, CF_3, $N(R)_2$, NO_2, CN, $-COR_8$, $-CONHR_8$, $-CON(R_8)_2$, $-O(CH_2)_nCOOR$, $-NH(CH_2)_nOR$, $-COOR$, $-OCF_3$, $-NHCOR$, $-SO_2R$, $-SO_2NR_2$, $-SR$, (C_1-C_6 alkyl)O-, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, (aryl)O-, -OH, (C_1-C_6 alkyl)$S(O)_m$-, H_2N-C(=NH)-, (C_1-C_6 alkyl)C(O)-, (C_1-C_6 alkyl)OC(O)NH-, -(C_1-C_6 alkyl)$NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)$O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)$S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)-C_{3-10} heterocyclyl-R_w, $-(CH_2)_n$-Z^1-C(=Z^2)$N(R)_2$, -(C_{2-6} alkenyl)$NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)$O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)$S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)-C_{3-10} heterocyclyl-R_w, -(C_{2-6} alkenyl)-Z^1-C(=Z^2)$N(R)_2$, $-(CH_2)_nSO_2R$, $-(CH_2)_nSO_3H$, $-(CH_2)_nPO(OR)_2$, $-(CH_2)_nOPO(OR)_2$, $-O(CH_2)_nSO_2R$, $-O(CH_2)_nPO(OR)_2$,-O $(CH_2)_nOPO(OR)_2$, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C_{2-6} alkenyl, and C_1-C_{10} alkyl, said alkyl, alkenyl, alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, and isothiazolyl optionally substituted with 1-3 groups selected from C_1-C_6 alkyl, COOR, SO_3H, OH, F, Cl, Br, I, and -$O(CH_2)_nCH(OH)CH_2SO_3H$;

Z^1 and Z^2 independently represents NR_w, O, CH_2, or S;

m is 0-3;
n is 0-3;
q is 0-2;

r is 0-6 and
p is 0-2,
provided that when R_4 and R_5 are hydrogen and YR_6 is ethyl then W is not tropine and when R_4 and R_5 are hydrogen and YR_6 is phenyl then W is not C_{1-4} alkyl.

2. Cancel.

3(Original). A compound according to claim 2 wherein W represents  and X represents CHR_7.

4(Original). A compound according to claim 2 wherein W represents $(CH_2)_nR_9$.

5(Original). A compound according to claim 3 wherein Y is $-CO(CH_2)_n$, $-(CH_2)_r$-or CH(OR) and Q is N or Ry.

6(Original). A compound according to claim 5 wherein R_6 is C_{1-10} alkyl, $(CH_2)_nC_{6-10}$ aryl, $(CH_2)_nC_{5-10}$ heteroaryl, $(CH_2)_nC_{3-10}$ heterocyclyl, or $(CH_2)_nC_{3-8}$ cycloalkyl, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a, Y is $-CO(CH_2)_n$, Q is N, and R_2 and R_3 are independently selected from C_{1-10} alkyl, $(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_n$-5~10-membered heteroaryl, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_n$-3~10-membered heterocyclyl, and C_{1-6} alkylOH said cycloalkyl, aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

7(Currently Amended). A compound which is:
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(5-Methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
Methyl [2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetate,
Methyl [2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetate,
[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*,*N*-bis(3-methylbutyl)acetamide,

1-(Diethoxymethyl)-6-methoxy-1*H*-benzimidazole,

1-(diethoxymethyl)-5-methoxy-1*H*-benzimidazole,

1-(6-Methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,

N,*N*-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*,*N*-diisobutylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*,*N*-dipropylacetamide,

N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol1-yl]-*N*-propylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,

N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,

[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetic acid,

2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*,*N*-bis(3-methylbutyl)acetamide,

N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1H-benzimidazol-1-yl]acetamide,

2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*,*N*-diisobutylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*,*N*-dipropylacetamide,

N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,

N-Butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,

N-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,

1-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,

1-(1-Benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,

1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-[1-(3,3-Dimethylbutyl)-5-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,

1-[1-(3,3-Dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
N,*N*-Dibutyl-2-[2-(2,2-dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,

N,*N*-Dibutyl-2-[2-(2,2-dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
1-[2-(2,2-Dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[2-(2,2-Dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[5-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,

1-[6-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(5-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(6-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
~~*N*,*N*-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(2-isobutyryl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(8-isobutyryl-2-methoxy-9*H*-purin-9-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(6-isobutyryl-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(6-isobutyryl-3-methoxy-5*H*-imidazo[4,5-*c*][1,2,4]triazin-5-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl]acetamide~~
~~*N*,*N*-dibutyl-2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(8-(2,2-dimethylpropanoyl)-2-methoxy-9*H*-purin-9-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)acetamide,~~
~~*N*,*N*-dibutyl-2-(6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*][1,2,4]triazin-5-yl)acetamide,~~
~~2-[2-(2,2-dimethylpropanoyl)-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl]-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(8-(2,2-dimethylpropanoyl)-2-methoxy-9*H*-purin-9-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~

~~2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-[6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*][1,2,4]triazin-5-yl]-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(8-isobutyryl-2-methoxy-9*H*-purin-9-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-(6-isobutyryl-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,~~
~~2-[6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*][1,2,4]triazin-5-yl]-*N*,*N*-bis(3-methylbutyl)acetamide,~~

1-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-dibutylacetamide,

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-butyl-*N*-ethylacetamide,

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-dipropylacetamide,

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(*tert*-butyl)-*N*-ethylacetamide,

2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,

[6-methoxy-1-(3-methylbutyl)-1*H*-benzimidazol-2-yl](phenyl)methanone,

[1-(2-ethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,

[1-(3,3-dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,

N-benzyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,

2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,

N,*N*-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,

N,*N*-diisobutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,

2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-dipropylacetamide,

N-(cyclopropylmethyl)-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,

N-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,

N-butyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,

N-cyclohexyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,

N-butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
1-(1-{2-[trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-{2-[cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-(2,2-dimethylpropyl)-*N*-ethylacetamide,
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*,*N*-bis(3-methylbutyl)acetamide,
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*,*N*-diisobutylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*,*N*-bis(3-methylbutyl)acetamide,
N-(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
N,*N*-bis(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
2-{2-[(4-cis-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*,*N*-bis(3-methylbutyl)acetamide,
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-bis(3-methylbutyl)acetamide,
N,*N*-dibutyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*,*N*-diisobutylacetamide,

N-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,
1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2,2-dimethylpropan-1-one,
1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2-methylpropan-1-one,
1-(2-benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(5-methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-[5-methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

8(Original). A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of structural formula I of claim 1.

9(Original). A method for treating macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a neuroprotective effect comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

10. Cancel.

11. Cancel.

12(Original). A composition comprising a compound of formula I of claim 1 and a pharmaceutically acceptable carrier.

13(Original). The composition according to Claim 12 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

14(Original). A composition according to claim 13 wherein one or more of an active ingredient belonging to the group consisting of: □-adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, EP4 agonist, a prostaglandin or derivative thereof, hypotensive lipid, neuroprotectant, and/or 5-HT2 receptor agonist is optionally added.

15(Original). A composition according to claim 14 wherein the □-adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imdazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.